| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 71 | 2025 | 1798 | 10.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 23 | 2025 | 188 | 4.300 |
Why?
|
| Androgen Antagonists | 21 | 2025 | 144 | 3.950 |
Why?
|
| Radiation Injuries | 9 | 2019 | 163 | 2.900 |
Why?
|
| Prostatectomy | 25 | 2025 | 480 | 2.810 |
Why?
|
| Anus Neoplasms | 5 | 2022 | 38 | 2.530 |
Why?
|
| Adenocarcinoma | 17 | 2019 | 1215 | 2.530 |
Why?
|
| Prostate-Specific Antigen | 25 | 2024 | 346 | 2.500 |
Why?
|
| Radiotherapy Dosage | 29 | 2025 | 482 | 2.460 |
Why?
|
| Chemoradiotherapy | 7 | 2021 | 327 | 2.350 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2025 | 1471 | 2.190 |
Why?
|
| Radiotherapy, Image-Guided | 6 | 2025 | 62 | 1.990 |
Why?
|
| Quality of Life | 8 | 2024 | 1816 | 1.840 |
Why?
|
| Salvage Therapy | 17 | 2025 | 238 | 1.740 |
Why?
|
| Radiotherapy, Conformal | 7 | 2016 | 89 | 1.710 |
Why?
|
| Rectal Neoplasms | 5 | 2024 | 134 | 1.570 |
Why?
|
| Fiducial Markers | 3 | 2025 | 11 | 1.500 |
Why?
|
| Aged | 65 | 2025 | 20968 | 1.490 |
Why?
|
| Urinary Incontinence | 4 | 2016 | 217 | 1.470 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2018 | 315 | 1.440 |
Why?
|
| Male | 97 | 2025 | 45863 | 1.440 |
Why?
|
| Anticoagulants | 5 | 2022 | 463 | 1.420 |
Why?
|
| Aged, 80 and over | 36 | 2024 | 7229 | 1.400 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2024 | 382 | 1.350 |
Why?
|
| Middle Aged | 67 | 2025 | 28368 | 1.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2024 | 154 | 1.250 |
Why?
|
| Humans | 118 | 2025 | 96105 | 1.190 |
Why?
|
| Prostate | 7 | 2023 | 423 | 1.140 |
Why?
|
| Radiosurgery | 6 | 2025 | 316 | 1.130 |
Why?
|
| Brachytherapy | 9 | 2025 | 127 | 1.130 |
Why?
|
| Head and Neck Neoplasms | 6 | 2021 | 1089 | 1.080 |
Why?
|
| Follow-Up Studies | 21 | 2024 | 3927 | 1.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2025 | 204 | 1.050 |
Why?
|
| Neoplasm Staging | 23 | 2023 | 2086 | 1.050 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 301 | 0.980 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2025 | 2777 | 0.980 |
Why?
|
| Combined Modality Therapy | 22 | 2024 | 1773 | 0.970 |
Why?
|
| Radiotherapy | 9 | 2019 | 328 | 0.940 |
Why?
|
| Fluorouracil | 7 | 2017 | 555 | 0.930 |
Why?
|
| Urogenital System | 4 | 2014 | 11 | 0.920 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 106 | 0.890 |
Why?
|
| Capecitabine | 5 | 2024 | 99 | 0.890 |
Why?
|
| Treatment Outcome | 27 | 2025 | 9175 | 0.860 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.850 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 426 | 0.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 2642 | 0.840 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 180 | 0.810 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 793 | 0.810 |
Why?
|
| Rectal Diseases | 3 | 2013 | 23 | 0.790 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2018 | 244 | 0.770 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 197 | 0.740 |
Why?
|
| Organs at Risk | 4 | 2025 | 48 | 0.720 |
Why?
|
| Radiation Oncology | 4 | 2021 | 124 | 0.710 |
Why?
|
| Aspirin | 2 | 2013 | 169 | 0.700 |
Why?
|
| Pancreatic Neoplasms | 4 | 2017 | 725 | 0.700 |
Why?
|
| Gastrointestinal Tract | 3 | 2013 | 197 | 0.700 |
Why?
|
| Patient Care Team | 1 | 2023 | 307 | 0.680 |
Why?
|
| Risk Assessment | 12 | 2020 | 2480 | 0.660 |
Why?
|
| Urinary Bladder | 3 | 2024 | 263 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 1105 | 0.650 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2017 | 39 | 0.650 |
Why?
|
| Cystectomy | 4 | 2024 | 114 | 0.650 |
Why?
|
| Hypersensitivity | 1 | 2022 | 166 | 0.640 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 3639 | 0.620 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 6 | 0.610 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 149 | 0.610 |
Why?
|
| Rectum | 4 | 2014 | 151 | 0.600 |
Why?
|
| Analysis of Variance | 9 | 2015 | 908 | 0.600 |
Why?
|
| Retrospective Studies | 25 | 2024 | 10287 | 0.600 |
Why?
|
| Prognosis | 16 | 2024 | 4028 | 0.590 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2025 | 1319 | 0.590 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 235 | 0.580 |
Why?
|
| Cohort Studies | 9 | 2025 | 3110 | 0.580 |
Why?
|
| Hematuria | 3 | 2022 | 50 | 0.580 |
Why?
|
| Neoplasm Grading | 9 | 2022 | 404 | 0.580 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 78 | 0.540 |
Why?
|
| Adult | 32 | 2020 | 28721 | 0.530 |
Why?
|
| Time Factors | 15 | 2020 | 5580 | 0.520 |
Why?
|
| Organ Transplantation | 1 | 2020 | 298 | 0.500 |
Why?
|
| Leukopenia | 1 | 2016 | 68 | 0.500 |
Why?
|
| Pelvic Bones | 1 | 2016 | 45 | 0.490 |
Why?
|
| Prospective Studies | 8 | 2022 | 4671 | 0.480 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2015 | 518 | 0.470 |
Why?
|
| Risk Factors | 10 | 2020 | 5961 | 0.470 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 191 | 0.460 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 995 | 0.460 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 1670 | 0.440 |
Why?
|
| Bone Marrow | 1 | 2016 | 458 | 0.440 |
Why?
|
| Sexuality | 1 | 2014 | 42 | 0.430 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 1010 | 0.430 |
Why?
|
| Tumor Burden | 5 | 2019 | 322 | 0.430 |
Why?
|
| Lymphatic Metastasis | 6 | 2024 | 514 | 0.400 |
Why?
|
| Survival Rate | 9 | 2019 | 1985 | 0.400 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2013 | 246 | 0.400 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 2418 | 0.400 |
Why?
|
| Urinary Retention | 2 | 2010 | 46 | 0.390 |
Why?
|
| Transurethral Resection of Prostate | 2 | 2010 | 10 | 0.390 |
Why?
|
| CA-19-9 Antigen | 1 | 2012 | 12 | 0.380 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 449 | 0.380 |
Why?
|
| Herpes Zoster | 1 | 2013 | 80 | 0.380 |
Why?
|
| Hospitalization | 1 | 2018 | 943 | 0.380 |
Why?
|
| SEER Program | 6 | 2020 | 235 | 0.370 |
Why?
|
| Chemoprevention | 1 | 2012 | 93 | 0.370 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 41 | 0.370 |
Why?
|
| Portal Vein | 1 | 2012 | 122 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 883 | 0.360 |
Why?
|
| Diabetes Complications | 1 | 2013 | 175 | 0.360 |
Why?
|
| Risk | 4 | 2020 | 668 | 0.350 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2591 | 0.350 |
Why?
|
| Radioimmunodetection | 2 | 2008 | 13 | 0.350 |
Why?
|
| Deoxycytidine | 2 | 2012 | 216 | 0.340 |
Why?
|
| Prostatism | 1 | 2010 | 5 | 0.330 |
Why?
|
| Lymph Nodes | 3 | 2020 | 565 | 0.330 |
Why?
|
| Urination Disorders | 1 | 2010 | 56 | 0.320 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 286 | 0.320 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 115 | 0.320 |
Why?
|
| Body Burden | 1 | 2009 | 10 | 0.310 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 257 | 0.310 |
Why?
|
| Withholding Treatment | 1 | 2010 | 121 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1096 | 0.310 |
Why?
|
| Survival Analysis | 9 | 2019 | 1546 | 0.300 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2016 | 192 | 0.290 |
Why?
|
| Smoking | 1 | 2013 | 653 | 0.290 |
Why?
|
| Models, Statistical | 1 | 2012 | 594 | 0.290 |
Why?
|
| Leucovorin | 3 | 2017 | 227 | 0.290 |
Why?
|
| Female | 24 | 2020 | 50028 | 0.280 |
Why?
|
| Comorbidity | 3 | 2021 | 1011 | 0.280 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2019 | 367 | 0.280 |
Why?
|
| Hemorrhage | 1 | 2009 | 294 | 0.260 |
Why?
|
| Disease Progression | 3 | 2020 | 1562 | 0.260 |
Why?
|
| Ganglioglioma | 1 | 2006 | 9 | 0.250 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 558 | 0.250 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 1196 | 0.250 |
Why?
|
| Treatment Failure | 4 | 2016 | 297 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 395 | 0.240 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 123 | 0.240 |
Why?
|
| Carcinoma | 2 | 2012 | 448 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2006 | 96 | 0.240 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2025 | 104 | 0.240 |
Why?
|
| Abdomen | 1 | 2006 | 127 | 0.240 |
Why?
|
| Postoperative Period | 3 | 2015 | 318 | 0.240 |
Why?
|
| Disease Management | 3 | 2024 | 360 | 0.230 |
Why?
|
| United States | 7 | 2021 | 7768 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 901 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 271 | 0.210 |
Why?
|
| Leuprolide | 1 | 2024 | 36 | 0.210 |
Why?
|
| Probability | 3 | 2012 | 365 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 247 | 0.210 |
Why?
|
| Urethral Neoplasms | 2 | 2018 | 10 | 0.210 |
Why?
|
| Motion | 1 | 2023 | 99 | 0.200 |
Why?
|
| Patient Selection | 3 | 2017 | 709 | 0.200 |
Why?
|
| Neoplasm, Residual | 3 | 2012 | 195 | 0.200 |
Why?
|
| Phenylthiohydantoin | 2 | 2022 | 48 | 0.200 |
Why?
|
| Ipilimumab | 1 | 2022 | 64 | 0.190 |
Why?
|
| Propensity Score | 2 | 2020 | 180 | 0.190 |
Why?
|
| Contrast Media | 2 | 2016 | 1096 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 1979 | 0.180 |
Why?
|
| Radiation Oncologists | 2 | 2021 | 15 | 0.180 |
Why?
|
| Incidence | 2 | 2022 | 1715 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2012 | 26 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1094 | 0.170 |
Why?
|
| Radium | 1 | 2020 | 7 | 0.170 |
Why?
|
| Oncologists | 1 | 2021 | 38 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 854 | 0.160 |
Why?
|
| Warfarin | 2 | 2012 | 107 | 0.160 |
Why?
|
| Platelet Count | 1 | 2020 | 97 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 4 | 2024 | 580 | 0.160 |
Why?
|
| Internship and Residency | 2 | 2021 | 1134 | 0.160 |
Why?
|
| Radiologic Health | 1 | 2019 | 2 | 0.150 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 20 | 0.150 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 12 | 0.150 |
Why?
|
| Depsipeptides | 1 | 2019 | 32 | 0.150 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 31 | 0.150 |
Why?
|
| Electrons | 1 | 2019 | 51 | 0.150 |
Why?
|
| Mitomycin | 2 | 2016 | 29 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2021 | 819 | 0.140 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 91 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 383 | 0.140 |
Why?
|
| Proctoscopy | 1 | 2017 | 1 | 0.140 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Digital Rectal Examination | 1 | 2017 | 5 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 1069 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 131 | 0.140 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 111 | 0.140 |
Why?
|
| Movement | 1 | 2020 | 324 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2860 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 100 | 0.130 |
Why?
|
| Neoplasms | 1 | 2013 | 3248 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2021 | 854 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 490 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2018 | 239 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 156 | 0.130 |
Why?
|
| Medicare | 1 | 2020 | 458 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 2039 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2019 | 297 | 0.130 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 47 | 0.130 |
Why?
|
| Camptothecin | 1 | 2017 | 204 | 0.120 |
Why?
|
| Remission Induction | 1 | 2018 | 769 | 0.120 |
Why?
|
| Internationality | 1 | 2016 | 76 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2022 | 766 | 0.120 |
Why?
|
| Ilium | 1 | 2016 | 31 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 2880 | 0.120 |
Why?
|
| Patient Safety | 1 | 2018 | 223 | 0.120 |
Why?
|
| Neutropenia | 1 | 2016 | 218 | 0.120 |
Why?
|
| Urology | 1 | 2017 | 133 | 0.120 |
Why?
|
| Software | 1 | 2020 | 698 | 0.120 |
Why?
|
| Seminoma | 1 | 2015 | 15 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 769 | 0.110 |
Why?
|
| Orchiectomy | 1 | 2015 | 63 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 873 | 0.110 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2014 | 30 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 502 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 58 | 0.110 |
Why?
|
| Carboplatin | 1 | 2015 | 331 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 245 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1137 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 625 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 436 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 35 | 0.100 |
Why?
|
| Radiography | 2 | 2006 | 826 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 26 | 0.100 |
Why?
|
| Enoxaparin | 1 | 2012 | 25 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1349 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 219 | 0.090 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 83 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 475 | 0.090 |
Why?
|
| Age Factors | 3 | 2010 | 1963 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2017 | 599 | 0.090 |
Why?
|
| Curriculum | 1 | 2016 | 615 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2012 | 446 | 0.080 |
Why?
|
| Proctitis | 1 | 2010 | 12 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1176 | 0.080 |
Why?
|
| Students, Medical | 1 | 2016 | 455 | 0.080 |
Why?
|
| Neck Dissection | 2 | 2008 | 68 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 310 | 0.080 |
Why?
|
| Algorithms | 2 | 2019 | 2015 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 157 | 0.080 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2010 | 49 | 0.080 |
Why?
|
| Seminal Vesicles | 2 | 2016 | 39 | 0.080 |
Why?
|
| Benzamides | 2 | 2022 | 248 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 3157 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 382 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 1805 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2013 | 504 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 713 | 0.070 |
Why?
|
| Urologic Diseases | 1 | 2009 | 42 | 0.070 |
Why?
|
| Registries | 3 | 2010 | 986 | 0.070 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 5 | 0.070 |
Why?
|
| Vitamin B Complex | 1 | 2008 | 21 | 0.070 |
Why?
|
| Acute Disease | 1 | 2010 | 872 | 0.070 |
Why?
|
| Indium Radioisotopes | 1 | 2007 | 10 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 7025 | 0.070 |
Why?
|
| Pharynx | 1 | 2006 | 45 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 138 | 0.060 |
Why?
|
| Recurrence | 1 | 2009 | 1218 | 0.060 |
Why?
|
| Cisplatin | 2 | 2024 | 611 | 0.060 |
Why?
|
| Re-Irradiation | 1 | 2025 | 17 | 0.060 |
Why?
|
| Chicago | 1 | 2009 | 1506 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 423 | 0.060 |
Why?
|
| Palliative Care | 1 | 2006 | 273 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 76 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 42 | 0.050 |
Why?
|
| Physics | 1 | 2021 | 21 | 0.040 |
Why?
|
| Mastectomy | 1 | 2004 | 270 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 179 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 89 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 185 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 516 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 298 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2006 | 3974 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 106 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 213 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 183 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 90 | 0.030 |
Why?
|
| Inflammation | 1 | 2004 | 1063 | 0.030 |
Why?
|
| Kallikreins | 1 | 2017 | 46 | 0.030 |
Why?
|
| Efficiency | 1 | 2017 | 41 | 0.030 |
Why?
|
| Pelvis | 1 | 2017 | 103 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 136 | 0.030 |
Why?
|
| Radiometry | 1 | 2016 | 61 | 0.030 |
Why?
|
| Job Satisfaction | 1 | 2017 | 86 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 427 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 125 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 128 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 131 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 182 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 363 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 713 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1791 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 935 | 0.030 |
Why?
|
| Child | 1 | 2006 | 7625 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 204 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 340 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 246 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 98 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 9895 | 0.030 |
Why?
|
| Fatigue | 1 | 2013 | 185 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1010 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1667 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 491 | 0.020 |
Why?
|
| Nomograms | 1 | 2007 | 35 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 236 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1957 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1179 | 0.010 |
Why?
|